Collegium Pharmaceutical Inc buy stratec
Start price
24.04.20
/
50%
€19.10
Target price
04.11.21
€28.00
Performance (%)
-13.61%
End price
05.11.21
€16.50
Summary
This prediction ended on 05.11.21 with a price of €16.50. The price of Collegium Pharmaceutical Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -13.61%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 3.593% | 3.593% | 73.000% | 84.043% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by stratec for this prediction
In the thread Collegium Pharmaceutical Inc diskutieren
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $33.83 average price target.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
In the thread Trading Collegium Pharmaceutical Inc
Die von stratec gewählte maximale Laufzeit wurde überschritten